Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
A director at Innate Pharma sold 10,000 shares at 5.500EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...
Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again Innate Pharma’s equity story received a significant boost of confidence on the back of ESMO 2021, with the presentation of its ANKET platform, but most remarkably – monalizumab’s success in combination with AstraZeneca’s anti-PD-L1, durvalumab (Imfinzi), as a maintenance therapy for stage III NSCLC. Recall, Monalizumab is being developed in collaboration with AZ and the amendment of the expected milestone payment left investors doubting AZ’s confidence in this programme. At ESMO 2021, AZ presented impressive interim res...
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 20...
KERING BUY | EUR775 Q3 slightly above expectations but Gucci even worse than expected Decline in retail sales growth in Q3 vs Q2 over 2Y due to APAC A sluggish Gucci performance in Q3, but other brands were strong! FY 2021 sales set to grow 8% on a 2Y track
DELIVERY HERO BUY | EUR177 Slower than expected decline in growth thanks to basket size Q3 growth to decelerate to mid-high double-digits Order frequency and basket size particularly resilient across the regions EBITDA estimate intact, waiting for confirmation of decline in vouchers Buy reiterated with a EUR177 TP
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.